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Abstract
We recently described our most potently neutralizing monoclonal antibody, E106, which protected against lethal Dengue
virus type 1 (DENV-1) infection in mice. To further understand its functional properties, we determined the crystal structure
of E106 Fab in complex with domain III (DIII) of DENV-1 envelope (E) protein to 2.45 A˚ resolution. Analysis of the complex
revealed a small antibody-antigen interface with the epitope on DIII composed of nine residues along the lateral ridge and
A-strand regions. Despite strong virus neutralizing activity of E106 IgG at picomolar concentrations, E106 Fab exhibited a
,20,000-fold decrease in virus neutralization and bound isolated DIII, E, or viral particles with only a micromolar monovalent
affinity. In comparison, E106 IgG bound DENV-1 virions with nanomolar avidity. The E106 epitope appears readily accessible
on virions, as neutralization was largely temperature-independent. Collectively, our data suggest that E106 neutralizes
DENV-1 infection through bivalent engagement of adjacent DIII subunits on a single virion. The isolation of anti-flavivirus
antibodies that require bivalent binding to inhibit infection efficiently may be a rare event due to the unique icosahedral
arrangement of envelope proteins on the virion surface.
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Introduction
Dengue virus (DENV) infection in humans causes symptoms
ranging from a mild febrile illness to a severe and sometimes fatal
disease. Over 3.6 billion people globally are at risk for DENV
infection, with an estimated 390 million infections annually and no
currently approved vaccine or antiviral therapy [1]. DENV
belongs to the Flaviviridae family of medically important positive-
stranded RNA viruses. Within the DENV serocomplex, there is
significant diversity, including four serotypes (DENV-1, -2, -3, and
4) that differ at the amino acid level of the envelope (E) protein by
,25 to 40 percent and multiple genotypes within a serotype that
vary by up to ,3 percent [2,3].
A humoral response against DENV infection is believed to
contribute to lifelong immunity against challenge by the homol-
ogous serotype. In comparison, protection against a heterologous
DENV serotype infection is more transient (,6 months to two
years) [4,5], allowing re-infection and disease to occur with a
heterologous serotype in hyper-endemic areas of the world.
Estimates suggest that greater than 90% of severe cases occur
during secondary infection with a heterologous DENV serotype,
possibly because sub-neutralizing amounts of cross-reactive
antibody facilitate viral entry into myeloid cells expressing Fc-c
receptors, a phenomenon termed antibody-dependent enhance-
ment of infection (ADE) [6]. Antibody-mediated protection against
homologous DENV infection correlates with a neutralizing
antibody response directed predominantly against the viral E
protein [7]. The ectodomain of E is comprised of three domains:
domain I (DI), a central nine-stranded b-barrel that connects
domain II (DII), which contains the fusion peptide at its distal end,
and an immunoglobulin-fold like domain III (DIII) [6–9].
Although neutralizing antibodies have been mapped to all three
domains of the E protein, many potently inhibitory anti-DENV
mouse MAbs map to DIII [10–17], specifically to the lateral ridge
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or A-strand epitopes, and block flavivirus infection at a post-
attachment stage, likely by preventing E protein dimer-to-trimer
transitions that are required for viral fusion [11,15,18].
We recently described a highly therapeutic MAb, DENV-1-
E106 (hereafter termed E106), which neutralized infection of
strains corresponding to all five DENV-1 genotypes and protected
against lethal DENV-1 infection when administered as a single
dose even four days after virus inoculation [13]. To understand the
basis for the potency (plaque reduction neutralization titer
(PRNT50) of 0.6 ng/ml) [13] and specificity of this MAb, we
solved the crystal structure of E106 Fab in complex with DENV-1
E DIII. Our analysis revealed a small antibody-antigen interface
with contact residues corresponding to two previously character-
ized DIII epitopes. Remarkably, a ,20,000-fold disparity in
neutralization by intact IgG and Fab correlated with distinct
abilities to bind intact virions. Our results are consistent with a
model in which our most potently inhibitory and therapeutic
DENV-1 MAb requires bivalent binding through dual and
simultaneous engagement of two antigen binding sites on a single
virion to neutralize infection. E106 is therefore one of only a few
unique antibodies described to date where effective neutralization
requires a bivalent binding mechanism, and is the first such
characterized MAb directed against flaviviruses.
Results
The crystal structure of E106 in complex with DIII reveals
a small footprint
E106 is a sub-complex specific therapeutic MAb that binds to
DENV-1 and DENV-4 infected cells and neutralizes infection of
all five DENV-1 genotypes efficiently (EC50 ranging from 1 to
50 ng/ml), without neutralizing DENV-2, 3 and 4 serotypes or
WNV [13]. The 2.45 A˚ crystal structure of E106 Fab bound to
DIII revealed only nine contact residues, from the A-strand (K307,
K310), the end of the B-strand (K325, Y326), and the connecting
BC (E327, T329, D330) and DE (K361, E362) loops (Fig. 1A and
Table 1); these results are consistent with prior mapping data by
yeast surface display, which implicated five of these residues as
essential recognition determinants (K310, T329, D330, K361 and
E362) [13]. Yeast surface display results also implicated G328,
P332, and P364 in E106 binding, and mutation of any of these
residues would likely result in an altered presentation of the direct
contact residues. Charge reversals at either E384 or K385 in the
FG-loop also diminished E106 recognition, and this loop is
adjacent to the primary E106 epitope. Overall, the contact
residues contributed 24 van der Waal interactions, 14 hydrogen
bonds, and 10 electrostatic interactions to the interface (Table
S1). The E106 structural footprint represents a unique composite
of previously identified DIII-specific neutralizing epitopes on
flaviviruses including the lateral ridge (N-terminal region, BC, DE
and FG loops) [19,20] and A-strand epitopes [10,21]. DENV-1
DIII was engaged by 11 heavy chain residues from CDR1 (I30,
G31, Y32 and Y33), CDR2 (N52, E50, and R53), and CDR3
(R95, I196, N97 and W98) (Fig. 1B, top panel) and four light
chain residues from CDR1 (D30, D32), CDR2 (E50), and CDR3
(L94) (Table S1).
A comparison of the DIII structure in complex with Fab versus
unbound DIII revealed small conformational differences, with a
root mean square displacement of 0.9 A˚ in the a-carbons over 98
residues. Of the DIII residues that directly interacted with the
E106 Fab, the greatest differences in a-carbon positions involved
residue T329 (1.2 A˚); this was significant because a recently
identified E106 MAb neutralization escape mutant showed a T to
A amino acid change at position 329 (Fig. 1B, bottom panel)
and [22]).
The E106 structural epitope on DIII was characterized by a
high shape complementarity score (Sc = 0.73, with a perfect fit
being 1) [23], which is greater than typical antibody-antigen
interactions (Sc = 0.64–0.68) [23] but similar to anti-flavivirus
MAb-E protein interactions (Table 2). The combined surface
area buried by the DIII-E106 Fab complex was ,1,243 A˚2
(Fig. 1C and Table 2) [24] which is less than most antibody-
antigen (1,400–2,300 A˚2) [25,26] and anti-flavivirus MAb-E
protein interactions (Table 2). Typical of many antibody-antigen
complexes, the majority (,70%) of the DIII-E106 Fab interface
was contributed by the heavy chain (Fig. 1C), with a combined
buried surface of 877 A˚2 (401 A˚2 of the heavy chain and 476 A˚2 of
domain III). The light chain contributed the remaining buried
surface (172 A˚2 of the light chain and 194 A˚2 of domain III).
All nine DIII contact residues were conserved in the five
DENV-1 genotypes (K361 is replaced by the conservative
substitution R361 in genotype 5 strains); this likely explains why
E106 neutralized infection of all five DENV-1 genotypes efficiently
(Fig. 1D and 1E), and [13]). In comparison, only one of the nine
contact residues (Y326) was conserved in DENV-2, DENV-3,
DENV-4 or WNV, a finding that is consistent with virological data
showing that DENV-1-E106 MAb neutralizes infection in a
serotype-specific manner [13]. E106 binds to DENV-4 but not to
DENV-2 or DENV-3 [13]. The number of conserved contact
residues did not correlate with DENV serotype binding specificity
(DENV-4 has four whereas DENV-2 and DENV-3 each have five,
Fig. 1E), which may instead be accounted for by other factors,
including differential maturation [27] or relative virion dynamics
[28].
E106 Fab binds DIII with micromolar monovalent affinity
To determine the significance of the small buried interface of
our E106-DIII complex, we investigated E106 binding to DIII by
surface plasmon resonance (SPR). Increasing concentrations of
purified DENV-1 DIII monomer were flowed over immobilized
Author Summary
Dengue virus (DENV) is a globally important mosquito-
transmitted human pathogen for which there is no
approved vaccine or antiviral therapy. In recent years,
the number and severity of DENV human infections have
increased due to the expanded geographic range of the
virus. Neutralizing antibodies are a key component of a
protective natural and vaccine-induced immune response
against human DENV infections. One recently described
monoclonal antibody (E106) protects mice against infec-
tion of DENV-1 when administered before or several days
after virus infection. Because of these results, we investi-
gated the mechanism of action of E106 using a combina-
tion of structural and functional approaches. E106
engaged an epitope on domain III of the viral envelope
protein that is a composite of two previously described
epitopes. Unexpectedly, and in contrast to the intact IgG,
Fab fragments of E106 were ineffective at neutralizing
virus; this was explained by their weak micromolar affinity
for virus particles. Our results suggest that neutralization
by E106, our most potently inhibitory and protective anti-
DENV MAb, requires bivalent binding of adjacent DIII
subunits on a single virion. Immunization strategies with
intact virions that skew the selection of neutralizing
antibodies to those with bivalently binding properties
could augment the potency of antiviral humoral responses
against DENV and other flaviviruses.
Bivalent Antibody Neutralization of Dengue Virus
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E106 Fab (Fig. 2A). Equilibrium analysis surprisingly revealed a
micromolar affinity (4.862.1 mM) for this interaction. A similar
result was observed when increasing concentrations of DENV-1-
DIII monomer was flowed over immobilized intact E106 MAb in
the solid phase (3.260.8 mM, Fig. 2B); this experiment eliminates
the possibility that papain cleavage and the removal of the E106
Fc region altered the monovalent binding parameters. Binding to
the ectodomain of DENV-1 E (DI-DII-DIII) also appeared
equivalently weak (1.160.1 mM). As an independent measurement
of affinity, we performed isothermal titration calorimetry under
similar experimental conditions as SPR by injecting DENV-1 DIII
into a solution of E106 Fab. Using this method with completely
unmodified proteins we again measured micromolar affinity for
the E106 Fab/DIII interaction (KD = 0.762 mM) (Fig. 2C).
E106 Fab binds and neutralizes DENV-1 poorly
The micromolar monovalent affinity of the highly therapeutic
E106 antibody was unanticipated in light of its picomolar
inhibitory activity (462 pM or 0.660.3 ng/mL; our most potent
neutralizing anti-flavivirus MAb isolated to date); as a comparison,
our therapeutic DIII-specific anti-WNV MAb E16 (inhibitory
activity 30 to 80 pM or 4–18 ng/mL), which has advanced to
human clinical trials [29], has a monovalent affinity of 3.4 nM
[30]. We hypothesized that while E106 MAb potently inhibited
DENV-1 infection, Fabs should lack this activity. To test this, we
compared the ability of Fab and intact IgG from E106 and E103,
a lateral ridge DIII-specific DENV-1 neutralizing antibody [13], to
inhibit infection. While monovalent E103 Fab showed a 114-fold
decrease in neutralization potency compared to the intact bivalent
IgG, the Fab of E106 Fab showed a remarkable 18,150-fold
decrease in inhibitory activity when compared to intact IgG
(Fig. 3A).
To investigate this observation further, we performed a virion-
binding assay by ELISA. DENV-1 virions (strain 16007) were
captured with humanized DIII A-strand-specific antibody
(DENV-1-E50) [31] and then detected with Fab or intact IgG of
E103, E106, or WNV E16 (negative control). Notably, the amount
of virus detected with E106 IgG was indistinguishable from E103
IgG (Fig. 3B). In comparison, E106 Fab bound virions to a
significantly lower level (P,0.0001) at all concentrations tested,
than those derived from E103 (Fig. 3B). Thus, disparate
neutralization of E106 MAb and Fab correlated with discordant
binding to DENV-1 virions and was consistent with the
biophysical measurements: monovalent binding by DENV-1-
E106 is surprisingly inefficient given the potent inhibitory activity
of intact antibody.
E106 MAb binds bivalently to DENV-1 virus particles
Based on these experiments, we hypothesized that efficient
neutralization of DENV-1 infection by E106 required bivalent
binding. Using bio-layer interferometry (BLI), we measured the
affinity and kinetics of MAb and Fab binding to intact DENV-1
virus particles [32] (Fig. 4). E106 MAb (Fig. 4A) bound DENV-1
particles with an apparent affinity (avidity), KDapp of 1362 nM. In
Figure 1. Crystal structure of E106 Fab in complex with DENV-1 E DIII. (A) The E106 Fab epitope on DENV-1 E DIII is comprised of residues in
the A-strand (K307 and K310), the end of the B-strand (K325 and Y326), and the connecting BC (E327, T329, and D330) and DE (K361 and E362) loops.
The immunoglobulin-like DIII is shown in blue (epitope regions in magenta), with the E106 heavy chain in green and light chain in cyan. (B) Heavy
chain residue W98 binds in a deep pocket contributed by the aliphatic groups of side chain DENV-1 E DIII residues K307, K325, and E327 and main
chain of Y326, in stereo (top panel). The electron density map is contoured at 1.1s. Ball and stick representation of the molecular interactions
involving T329 (the residue that escapes neutralization [13] in stereo (bottom panel). (C) Surface representation of DENV-1 E DIII (top) and E106 Fab
(bottom) highlighting residues making direct contacts in the complex (see Table S1). DENV-1 E DIII residues previously identified by yeast surface
display are displayed in magenta [13]. (D) The structural epitope on DENV-1 DIII is shown in ribbon representation. (E) Sequence of DIII of DENV-1
aligned with that of DENV-2, -3, -4 and WNV highlighting the E106 structural epitope, which is conserved in DENV-1 genotypes but not DENV
serotypes or WNV. Identical residues are represented by a dot, deleted residues by a hash. For comparison, The DIII structural epitopes of WNV E16,
DENV-2 1A1D-2, DENV cross-reactive 4E11 and 2H12 MAbs and DENV-1-E111 contact residues are labeled with green, purple, light purple, orange
and cyan asterisks respectively [10,17,20,21,33].
doi:10.1371/journal.ppat.1004072.g001
Bivalent Antibody Neutralization of Dengue Virus
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Table 1. Data collection and refinement statisticsa.
Wavelength 0.976 A˚
Resolution 20 – 2.45 A˚ (2.54-2.45 A˚)
Number of observed reflections 166 322
Unique reflections 26 014
Redundancy 6.4 (4.8)
I/sI 19.8 (2.1)
Rmergeb 0.083 (0.546)
Completeness 99.5% (95.9%)
Spacegroup P212121
Cell dimensions a = 82.7 A˚, b = 91.8 A˚, c = 92.6 A˚; a= b= c= 90u
Refinement statistics
Resolution 20-2.45 A˚ (2.55 - 2.45 A˚)
No. of reflections/No. in Rfree 25912/1134
Rcryst/Rfree
c 18.9%/23.9%
No. atoms protein/solvent 4063/94
,B. protein 59.2 A˚2
,B. solvent 49.3 A˚2
Rmsd bond lengths 0.004 A˚
Rmsd bond angles 0.822u
Ramachandran favoured 97.5%
Ramachandran allowed 2.5%
Ramachandran outliers 0%
Molprobity scored 1.07
Molprobity clash score 1.99
PDB ID 4L5F
aNumbers in parentheses refer to the highest resolution shell.
bRmerge =S|I2,I.|/S,I., where I is the intensity of each individual reflection.
cR=g(FP2Fcalc)/gFP.
dMolprobity score defined as 0.42574 * log(1+clashscore)+0.32996 * log(1+max(0,pctRotOut-1))+0.24979 * log(1+max(0,1002pctRamaFavored-2))+0.5.
doi:10.1371/journal.ppat.1004072.t001
Table 2. DENV-1 DIII-E106 Fab structural interface.
Aba – Agb complex Ag (A˚2) Ab (A˚2) Ag+Ab (A˚2) Scc
E106 – DENV1 DIII 670 573 1 243 0.73
E16 – WNV DIII 789 810 1 599 0.76
1A1D-2 – DENV2 DIII 914 936 1 850 0.44
E53 – WNV E 596 581 1 177 0.66
E111 – DENV1 DIII 1010 1085 2095 0.68
2H12 – DENV1 DIII 652 630.5 1305.2 0.76
2H12 – DENV3 DIII 589 544 1132 0.79
2H12 – DENV4 DIII 518–548 464–488 982–1036 0.76–0.79
4E11 – DENV1 DIII 877 910 1787 0.71
4E11 – DENV2 DIII 886 876 1762 0.73
4E11 – DENV3 DIII 723–775 742–751 1474–1517 0.77
4E11 – DENV4 DIII 883 879 1762 0.74
The structural interface of DENV-1 DIII-E106 Fab (described by the surface area of antibody, Aba and antigen, Agb that is buried [24] as well as shape complementarity,
Scc in the complex [23]) is compared to previously determined anti-DENV and anti-WNV Fab complexes. PDB codes E16 – WNV E DIII, 1ZTX [20]; 1A1D-2 – DENV2 E DIII,
2R29 [21]; E53 – WNV E, 3I50 [43]; E111 – DENV1 E DIII, 4FFY [33]; 2H12 – DENV1 DIII, 4AL8 [17]; 2H12 – DENV3 DIII, 4ALA [17]; 2H12 – DENV4 DIII, 4AM0 [17]; 4E11 –
DENV1 DIII, 3UZQ [10]; 4E11 – DENV2 DIII, 3UZV [10]; 4E11 – DENV3 DIII, 3UZE [10]; 4E11 – DENV4 DIII, 3UYP [10].
doi:10.1371/journal.ppat.1004072.t002
Bivalent Antibody Neutralization of Dengue Virus
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contrast, E106 Fab had an affinity of KD.1 mM, with a rapid
dissociation rate (t1/2,2 sec) that was at least 800-fold faster than
E106 MAb (t1/2.400 sec) (Fig. 4B). These results contrast with
more comparable binding of E103 MAb (KDapp of 0.860.1 nM)
(Fig. 4C) and E103 Fab (KD of 761 nM) to DENV-1 particles
(Fig. 4D). Importantly, the binding affinities of E106 Fab
engaging isolated DIII measured by SPR and ITC is remarkably
similar to that observed by BLI for the binding to DENV-1 virions,
suggesting that our structurally defined DIII epitope corresponds
to the entire virion surface recognized by a single Fab.
Mechanistic correlates of E106 MAb neutralization
We next investigated the time- and temperature-dependence of
E106 neutralization, as this analysis can provide information as to
the relative accessibility of epitopes [28,33]. Changes in the time or
temperature of incubation did not appreciably affect E106
neutralization (Fig. 5A and B). By performing pre- and post-
attachment neutralization assays, we found that, similar to several
other potently neutralizing DIII-specific antibodies against flavivi-
ruses [15,30,34], E106 can neutralize infection even after virus
attaches to cells (Fig. 5C). Finally, we tested the neutralization of
E106 MAb as a function of the maturation state of the virus. DENV
virions are a heterogeneous mixture of immature, partially mature
and fully mature virions, with immature virions being generally less
or non-infectious. In this assay, E106 MAb neutralization proved to
be independent of the maturation state of the virus (Fig. 5D). In
comparison, neutralization by E60, a DII fusion-loop-specific MAb,
was sensitive to virion maturation, as seen previously [27].
Modeling of E106 binding to virus
In contrast to non-enveloped viruses where a structural
understanding of bivalent antibody binding has emerged [35–
37], there currently is no such data for icosahedral enveloped
viruses including flaviviruses. To address how E106 might
recognize DENV-1 bivalently we docked our structure onto the
cryo-EM derived model of the mature DENV virion (Fig. 6) [38].
While the E106 epitope is predominantly exposed on all 180 E
protein monomers (Fig. 6A), unimpeded binding is readily
apparent only on monomers in the 3-fold and 2-fold symmetry
axes, similar to what we observed for E16 binding to WNV
[20,39]. However, minor reorientation of DIII subunits on the
inner 5-fold symmetry axis would allow for up to two E106 Fabs to
bind there at the same time as three Fabs could bind to the outer
5-fold (2-fold) related epitopes. We measured the distance
Figure 2. E106 Fab and MAb binds with low affinity to DENV-1-DIII. Analysis of DENV-1 DIII binding to (A) E106 Fab and (B) E106 MAb as
measured by SPR. The kinetically fit sensorgrams (fits in gray, raw data in black) for which a 5.863.0 mM affinity (Fab) and 4.261.2 mM (MAb) was
calculated on the left panel is similar to the equilibrium data fit 4.862.1 mM (Fab) and 3.260.8 mM (MAb) which is shown on the right panel. (C) ITC
confirms a micromolar affinity of E106 Fab for DENV-1 DIII. Results are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1004072.g002
Figure 3. Fab versus MAb neutralization and binding. (A) DENV-1 neutralization by E106 MAb (filled square, red) and Fab (empty square,
salmon) (upper panel) and corresponding fold reduction (lower panel). The control E103 MAb (filled circle, blue) and corresponding Fab (empty circle,
purple) is included for comparison. (B) Qualitative ELISA binding of MAbs and Fabs to DENV-1. E106 MAb binds virions to a similar extent as E103
MAb but E106 Fab binding is significantly less than E103 Fab (P,0.0001). The negative control is E16. The results are from two ELISA experiments
performed in duplicate and without background subtraction. The limit of detection was determined by performing the assay in the absence of virus.
doi:10.1371/journal.ppat.1004072.g003
Bivalent Antibody Neutralization of Dengue Virus
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separating the docked Fab CH1 domain C-termini with the
expectation that distances greater than 50 A˚ would be unlikely
spanned by 16 hinge residues [36,37]. This analysis indicated the
possibility for limited bivalent bridging, with the primary
candidates being adjacent outer 5-fold epitopes (49 A˚ CH1
separation) (Fig. 6B and D) as well as adjacent inner and outer
Figure 4. Fab and MAb binding to DENV-1 RVPs. (A) E106 MAb binding to DENV-1 RVPs by bio-layer interferometry. E106 MAb binds with high
apparent affinity to DENV-1 RVPs (KDapp of 1362 nM) with a slow dissociation (t1/2.400 sec). Raw data is in red and fits are in gray. (B) Direct binding
of E106 Fab to DENV-1 RVPs. Results are representative of several independent experiments that showed low affinity binding (KD of .1 mM) and fast
off-rate kinetics (t1/2,2 sec). Raw data is in salmon and fits are in gray. BLI determined binding of the control E103 (C) MAb and (D) Fab to DENV-1
RVPs. E103 MAb and Fab binding to DENV-1 RVPs are comparable, with a calculated apparent KDapp of 0.860.1 nM and KD of 761 nM, respectively, as
expected for a predominantly monovalent interaction. Raw data is in blue (E103 MAb) and purple (E103 Fab) and fits are in gray. Results are
representative of at least two independent experiments.
doi:10.1371/journal.ppat.1004072.g004
Figure 5. Functional characteristics of neutralization by E106 MAb. (A–B) Time and temperature dependence of neutralization. DENV-1 RVPs
were pre-incubated with E106 MAb for one (A) or five hours (B) at three different temperatures (4uC, 37uC and 40uC) before infecting Raji-DCSIGNR
cells. Infection was carried out at 37uC and assessed 48 h later by flow cytometry. Error bars represent the standard error of the mean of duplicate
infections. Results are representative of two independent experiments. (C) Pre- or post-attachment neutralization test. BHK21-15 cells were pre-
chilled to 4uC, and 102 PFU of DENV-1 (strain 16007) was added to each well for one hour at 4uC. After extensive washing at 4uC, increasing
concentrations of E106 MAb were added for one hour at 4uC, and the PRNT determined (triangles, Post). A standard pre-incubation PRNT with all
steps performed at 4uC is shown for reference (squares, Pre). Data shown are representative from three experiments performed in duplicate. (D) E106
MAb neutralization is insensitive to the maturation state of the virus. E106 MAb neutralization of immature, standard, and mature 16007 RVP
preparations, independently validated with the fusion-loop specific E60 MAb, are shown. A representative neutralization assay of three experiments is
depicted. Error bars represent the standard error of the mean of duplicate infections. The inset depicts the EC50 values of neutralization of the
distinct RVP preparations (immature, standard and mature) by E106 MAb and the control E60 MAb.
doi:10.1371/journal.ppat.1004072.g005
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5-fold epitopes (24 A˚ CH1 separation) (Fig. 6C and D). These
epitopes are 85 A˚ and 79 A˚ apart, respectively, within the
expected reach of a single IgG molecule (117–134640 A˚) [40].
We also examined the E106 epitope on the recent cryo-EM
reconstruction of DENV-2 at 37uC [41,42]; this ‘bumpy’ virion
supports a similar model of bivalent binding to DIII on the 5-fold
and 2-fold symmetry axes.
Discussion
Epitope mapping studies have enhanced our understanding of
the mechanisms of virus neutralization and identified sites on the E
protein of flaviviruses that are targeted by neutralizing antibodies
[7]. These include the lateral ridge of DIII of WNV and JEV
[19,20], the A-strand of DIII of DENV [10,21], the CC9 loop of
DIII of DENV-1 [33], the fusion loop of DII of WNV and DENV
[43], a DI epitope of DENV-4 [11], and a complex epitope centered
at the hinge of DI and DII on WNV [44] and DENV [45,46]. Here,
we describe a composite epitope, comprised of regions of the lateral
ridge and A-strand of DIII that is targeted by the therapeutic MAb
E106. DIII residues contacted by E106 were highly conserved
among DENV-1 genotypes but variable in other DENV serotypes.
Consistent with this, E106 potently neutralized all five DENV-1
genotypes, but not other DENV serotypes nor WNV [13].
The E106 Fab-DIII complex was characterized by a small-
buried interface, which correlated with an unexpectedly weak
micromolar affinity, as determined both by SPR and isothermal
calorimetry. We found no evidence for E106 binding to residues
outside of DIII as the binding affinity to recombinant DIII appears
to be very similar to the binding of Fab to E ectodomain protein or
virions; consistent with this, neutralization escape studies only
identified residues in DIII [22]. Monovalent E106 Fab poorly
neutralized DENV-1 compared to intact E106 IgG, and this
finding correlated with poor binding of Fab to intact virus.
Although our structural models suggest that E106 can readily bind
the isolated pre-fusion dimer and post-fusion trimer and possibly
prevent the ,70u transition of DIII that is associated with
membrane fusion [47,48], the inability of E106 Fab fragments to
neutralize virus efficiently argues against this model. Our data are
more consistent with a mechanism of neutralization that requires
bivalent binding of E106 IgG to single virions, and cross-linking of
E protein monomers in adjacent symmetry groups to prevent
requisite E protein rearrangements during infection.
The measurement of micromolar monovalent affinity was
unexpected given that E106 is our most potently neutralizing
and protective anti-DENV-1 MAb (EC50 of 0.6 ng/ml against
DENV-1 strain 16007), which is at least 10-fold more potent than
our well-characterized DIII-lateral ridge-specific therapeutic MAb
(E16) against WNV [20,30]. Indeed, E106 had the lowest EC50
value of ,500 anti-flavivirus MAbs (DENV-1, DENV-2, DENV-
3, DENV-4, and WNV) generated to date in our laboratory
[13,15,30,49]. Is there a correlation between neutralization
potency and E106 bivalent binding to single virions? The
icosahedral arrangement of the E protein on the mature DENV
virion displays 180 copies of the E protein. Our in silico modeling
predicts that in one possible arrangement, up to 48 of these sites
may be available for bivalent engagement by 24 intact E106 IgG.
Since monovalent binding was insufficient for neutralization,
bivalent binding to single virions could neutralize infection by
inhibiting an essential stage of the virus lifecycle (attachment,
entry, or fusion). Alternatively, bivalent binding across virions
could neutralize DENV infection by aggregating virus. Our post-
attachment studies suggest that E106 MAb was capable of
neutralizing infection even after virus attached to the cell surface.
Aggregation also appears less likely because the neutralization
curves did not show a characteristic triphasic dose-response curve
that was reported in inhibition studies describing antibody-virus
aggregation [50]. We favor a model in which bivalent binding of
E106 stabilizes and/or cross-links one or more E protein
monomers in different symmetry groups, analogous to monovalent
binding of WNV CR4354 MAb [44], and thus prevents radial
expansion and rearrangement that is requisite for fusion of viral
and host endosomal membranes [48,51].
E106 is one of very few MAbs that have been shown to require
bivalent binding for efficient virus neutralization [35,36,52], and
the first one directed against a flavivirus. While antibodies can be
multivalent, with the potential to bind to virus particles with high
avidity, the relatively small number of bivalent binding MAbs
described to date may be attributed to the following: (i) the limited
number of epitopes displayed on a single particle for some viruses;
Figure 6. Modeling of E106 binding to DENV. (A) The E106 epitope is highlighted in magenta on a DENV-1 model of the DENV-2 cryo-electron
microscopic reconstruction (PDB code 1P58). All atoms of the model are displayed and colored by domains (DI, red; DII, gold; DIII, blue). Magnified
view of the boxed region in (A) with E106 Fab docked onto the epitopes at the primary candidates for bivalent antibody binding namely (B) adjacent
2-fold epitopes (49 A˚ CH1 separation) which is permuted as an outer 5-fold ring and (C) adjacent inner and outer 5-fold epitopes (24 A˚ CH1
separation). E106 Fab heavy and light chain is represented by green and cyan spheres, respectively. The C-terminal CH1 residue is represented by ‘C’.
(D) Schematic of the possible arrangements of E106 MAb bivalent binding to the lateral ridge plus A-strand epitope (magenta) on a single virion. The
distances labeled in magenta and green are E106 epitope (T329) and C-terminal CH1 residue (R214) distances respectively. One Fab pair (green, heavy
chain; cyan, light chain) is shown across the 5- and 2-fold and another involves adjacent 2-fold symmetry axes (the 2-fold permutes as an outer 5-fold
ring, dashed gray line). 5-, 3- and 2-fold axes of symmetry are connected by gray dashed lines for clarity and represented by pentagons, triangles, and
ovals, respectively. Epitopes that are occluded as a result of bivalent binding are shown in gray.
doi:10.1371/journal.ppat.1004072.g006
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(ii) the position and orientation of epitopes that are beyond the
reach of a bivalent MAb, which is limited by torsional flexibility of
its hinge; (iii) the radius of curvature of virions, which may restrict
the accessibility of epitopes by MAb (iv) post-translational
modification (e.g. N-linked glycans) of virions that may hinder
bivalent MAb engagement; (v) immunization protocols that rely on
isolated recombinant envelope proteins, rather than envelope
proteins in the structurally unique form of the intact virion; and
(vi) assays that do not screen for bivalent neutralizing MAbs. E106
was generated after priming and boosting with infectious DENV-1
[13]. The repetitive E antigens in the icosahedral orientation of the
virion may have facilitated selection of low monovalent affinity yet
high avidity antibodies. While some antibodies against HIV have
been described as bivalent, they actually are bispecific, with each
arm binding distinct epitopes [53]. This is likely due to the paucity
of trimeric spikes on the surface of the virus (,14) and their
irregular spacing [54]. Although several MAbs have been
proposed to require bivalent binding for efficient virus neutrali-
zation [55,56], compelling evidence is presented only for the non-
enveloped positive strand RNA viruses, specifically, human
rhinovirus 2 [36] and 14 [35,52] and the rabbit hemorrhagic
disease calicivirus [37]. It may be that the quasi-icosahedral
arrangement of the flavivirus envelope creates a landscape that
permits limited bivalent MAb engagement.
Bivalent engagement of the virion by antibodies could be an
important concept for DENV vaccine development. Immunity
against DENV may not be achieved optimally using a subunit
vaccine approach, as isolated E protein monomers may not induce
antibodies that require bivalent binding for strong binding and
neutralization. Analogously, some human MAbs against WNV bind
a complex epitope at two independent positions on adjacent E
protein monomers in different symmetry groups, which is only
present on an intact WNV particle [44]. Human MAbs isolated
from DENV-infected individuals are believed to recognize similar
quaternary epitopes in E that are present only in the context of the
intact DENV virion [45,46]. Given that E106 MAb was our most
potent and therapeutic anti-DENV-1 MAb, strategies that enhance
the likelihood of generating and identifying neutralizing antibodies
that function through bivalent binding mechanisms may improve
the potency of inhibitory humoral responses against DENV and
other flaviviruses. Regardless, an understanding of the structural
and mechanistic basis for the neutralization activity of E106 MAb
provides new insights into the humoral response against flaviviruses.
Materials and Methods
E106 Fab-DIII crystal structure determination
DENV-1 DIII (residues 293 to 399 of the E protein of strain
16007) was expressed in bacteria and re-folded oxidatively from
isolated inclusion bodies as described previously [13]. Fab
fragments of E106 were prepared using immobilized papain resin
according to the manufacturer’s instructions (Pierce). MAb (5 to
10 mg) was digested for 18 hours at 37uC, and passed over a
protein A agarose resin to remove Fc fragments and undigested
MAb and purified on a S-75 size exclusion chromatography
column equilibrated in 20 mM HEPES pH 7.4 and 150 mM
NaCl. Antibody–antigen complexes were formed by mixing
papain-generated, gel filtered E106 Fab fragments with DIII at
a ratio of 1.2:1 and crystallized by the hanging drop vapor
diffusion method at a total protein concentration of 14 mg/mL in
a solution of 22% PEG 6,000, and 0.1 M MES pH 5.0 (final
pH 5.7). Crystals (in 1 mL crystallization drops) were cryopro-
tected by the addition of 0.2 mL aliquots of cryobuffer (in 23.5%
PEG 6,000, 0.1 M MES pH 5.0, final pH 5.7, and 20% glycerol),
then transferred to a fresh drop of cryobuffer and rapidly cooled in
liquid nitrogen. X-ray diffraction data were collected at ALS
beamline 4.2.2 (Lawrence Berkeley Laboratories) at a wavelength
of 0.976 A˚ at 100 K with a CCD detector, and indexed and scaled
in HKL2000 [57]. The crystals diffracted to 2.45 A˚ resolution and
belonged to the space group P212121 with unit cell dimensions of
a = 82.7 A˚, b = 91.8 A˚, c = 92.6 A˚, with one E106 Fab-DIII
complex per asymmetric unit. Crystallographic phasing was
obtained by molecular replacement using the program Phaser
[58] and the coordinates of DENV-1 DIII (Protein Data Bank
(PDB) 3EGP) and the Fab fragment of CTM01 IgG (PDB 1AD9).
Iterative model building and refinement was performed using
Coot [59] and Refmac [60] and later Phenix [61]. The final
structure was refined to Rcryst = 18.9% and Rfree = 23.9%. The
final model includes DENV-1 DIII amino acid residues 297 to
394, E106 heavy chain residues 1 to 214 (Chothia numbering),
and light chain residues 1 to 213. The atomic coordinates and
structure factors of E106 Fab bound to DENV-1 DIII (CSGID
target number IDP00272) have been deposited in the Protein Data
Bank (www.rcsb.org) under PDB accession number 4L5F.
Structural figures were prepared using CCP4MG [62] and Pymol
[63] (surface representation using 1.4 A˚ solvent probe) and where
shown, spheres represent van der Waal radii, vdw * 1.1.
Surface plasmon resonance and isothermal titration
calorimetry
Monovalent antibody affinity analysis was performed using SPR
(BIAcore T100, GE Company) and ITC (VP-ITC instrument,
Microcal) at 10uC in 50 mM HEPES, pH 7.5 and 100 mM NaCl.
For SPR, E106 MAb or Fab was immobilized at low concentrations
(,500 Response Units) to a CM5 chip (GE healthcare) using amine-
coupling chemistry. Bacterially-expressed DIII (residues 293–399)
of DENV-1 (strain 16007) was injected at a flow rate of 65 ml/min at
concentrations ranging from 0.2 mM to 500 mM for three minutes
to saturate binding and then allowed to dissociate for seven minutes.
The half-life of the monovalent interaction was short and did not
require additional regeneration of the chip surface in preparation
for the next DIII injection. The observed binding curves were
double referenced to a non-reactive antibody (WNV E16) as well as
buffer in the absence of DIII. Curves were analyzed by a steady-
state fit for a 1:1 interaction, and a nonlinear least squares fit was
used to evaluate the fit of the curve to the observed data.
Alternatively, 500 response units (RU) of DIII were immobilized
onto a CM5 chip and E106 Fab fragments were injected to
saturation. Affinity measurements of E106 for the DENV-1 E
ectodomain (DI-DII-DIII) were performed such that insect-derived
DENV-1 E glycoprotein (ProSpec-Tany TechnoGene Ltd.) was in
the stationary phase and E106 Fab fragments were in the mobile
phase, in order to conserve limited protein and avoid avidity affects.
Additional regeneration was not necessary because of the short half-
life for the interaction. WNV E ectodomain was used as a negative
control for E106 binding. Analysis was performed as with the DIII
described above. ITC experiments were performed such that 4 to
8 mL of DENV-1-DIII protein (90 to 110 mM) was injected into
1.4 mL of E106 Fab protein (6 to 7 mM) over a total of 36 injections.
The titration data were integrated and normalized in Origin
(Microcal) to determine the reaction stoichiometry, n, and
equilibrium constant Ka ( = K21d).
Neutralization assays and capture ELISA
Plaque reduction neutralization tests (PRNT) and pre- and post-
attachment neutralization assays were performed with DENV-1
strain 16007 on Vero cells as previously described [13,64]. Binding
of intact MAbs or Fabs (E103, E106, and a negative control WNV
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E16) to DENV-1 virions (strain 16007) was detected by capture
ELISA [13,64]. Briefly, humanized DENV-1 E50 MAb (subcom-
plex DIII A-strand specific antibody) was coated at 2 mg/ml on
MaxiSorp (Nunc) polystyrene 96-well microtiter plates in a sodium
carbonate (pH 9.3) buffer. Plates were washed three times in wash
buffer (PBS with 0.02% Tween 20) and blocked for one hour at
37uC with blocking buffer (DMEM with 10% FBS). DENV-1
virions (2.56105 PFU) diluted in DMEM with 10% heat-inactivat-
ed FBS were captured on plates for two hours at 37uC. Wells were
washed thrice with blocking buffer and DENV-1 MAb or Fab was
then added at 100 mg/ml and 4-fold serial dilutions to duplicate
wells and incubated for two hours at 37uC. Plates were washed five
times and then sequentially incubated with goat anti-mouse (whole
molecule) IgG-HRP (Sigma, St Louis, MO) and tetramethylbenzi-
dine substrate (Dako). The reaction was stopped with the addition of
2 N H2SO4 to the medium, and emission (450 nm) was read using
an iMark microplate reader (Bio-Rad).
Time and temperature-dependent neutralization of
DENV-1
A plasmid expressing the C-prM-E genes of DENV-1 (strain
16007) was co-transfected into HEK-293T cells with a plasmid
encoding a WNV replicon expressing GFP. Transfected cells were
incubated at 30uC and RVP harvested at 72 and 96 hours post-
transfection, filtered through a 0.2 mM filter, and stored aliquoted
at 280uC. DENV-1 RVP were incubated with serial dilutions of
MAb under conditions of antibody excess at 4uC, 37uC, or 40uC
for one or five hours. Subsequently, MAb-RVP mixtures were
added to Raji-DCSIGNR cells and incubated at 37uC for
48 hours. Infected cells were assayed for GFP expression using a
BD FACSCalibur flow cytometer as described [28].
The kinetics of DENV-1 RVP binding to DENV-1 MAbs and
Fabs
All bio-layer interferometry studies were performed in PBS buffer
supplemented with 1 to 2 mg/ml BSA (PBS-B) at 25uC using an
Octet Red biosensor system (ForteBio). DENV-1 reporter virus
particles (RVPs) (Western Pacific 74 strain) were produced as
previously described [65]. To purify virus particles, RVP produc-
tion supernatant was harvested, clarified through a 0.22 mm filter
(Corning), and PEG precipitated using 7.5% PEG 8000 (Sigma).
The virus particles were further purified through two 20% sucrose
cushions before resuspension in HBS. Samples were stored at 2
80uC and gently thawed prior to use. RVPs were loaded onto
streptavidin (SA) biosensor tips using a human monoclonal antibody
against DENV-1 (1H7.2, the anti-prM antibody, a gift from James
Crowe), which was captured using a biotinylated goat anti-human
polyclonal antibody (GAH Fc, Southern Biotech). Briefly, GAH Fc
was diluted to 5 mg/ml in PBS-B and bound to SA sensor tips for
five minutes. Following a brief rinse in PBS-B, 1H7.2 (5 mg/ml in
PBS-B) was captured for five minutes. After another brief rinse,
DENV-1 RVPs diluted to 10 mg/ml (or 50 mg/ml (E106 Fab)) were
loaded for 45 minutes followed by a five-minute stabilization.
Antibody association was measured for up to 10 minutes followed
by dissociation for 20 minutes (E106) or 45 minutes (E103) in
buffer. Non-specific binding was assessed using sensor tips without
RVPs as well as using sensor tips loaded with retroviral pseudotypes
(Lipoparticles) containing only endogenous cell surface receptors (no
viral envelope protein). Data analysis was performed using Octet
Data Analysis v6.4 (ForteBio). Binding kinetics were analyzed using
a standard 1:1 binding model.
Supporting Information
Table S1 E106/DENV1-DIII interface.
(DOCX)
Acknowledgments
The authors would like to thank J. Nix at ALS beamline 4.2.2 (Lawrence
Berkeley Laboratories) for help with X-ray data collection, J. Brien for
helpful discussions, F. J. Smith for computational assistance, and B. Doranz
for editorial comments on the manuscript.
Author Contributions
Conceived and designed the experiments: MAE SKA KAD MSD DHF.
Performed the experiments: MAE SKA BS KAD MNM CAN. Analyzed
the data: MAE SKA BS KAD CAN JR TCP MSD DHF. Contributed
reagents/materials/analysis tools: SM EAC SJ. Wrote the paper: MAE
SKA MSD DHF.
References
1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The
global distribution and burden of dengue. Nature 496: 504–507. doi:10.1038/
nature12060.
2. Rico-Hesse R (1990) Molecular evolution and distribution of dengue viruses type
1 and 2 in nature. Virology 174: 479–493. doi:10.1016/0042-6822(90)90102-W.
3. Holmes EC, Twiddy SS (2003) The origin, emergence and evolutionary genetics
of dengue virus. Infect Genet Evol 3: 19–28. doi:S1567134803000042 [pii].
4. Sabin AB (1952) Research on dengue during World War II. Am J Trop Med
Hyg 1: 30–50.
5. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, et al. (2013) Interactions
between serotypes of dengue highlight epidemiological impact of cross-
immunity. J R Soc Interface 10. doi:10.1098/rsif.2013.0414.
6. Halstead SB (1989) Antibody, macrophages, dengue virus infection, shock, and
hemorrhage: a pathogenetic cascade. Rev Infect Dis 11 Suppl 4: S830–9.
doi:10.1111/j.1742-4658.2005.04870.x.
7. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS (2008) Structural insights
into the mechanisms of antibody-mediated neutralization of flavivirus infection:
implications for vaccine development. Cell Host Microbe 4: 229–238.
doi:S1931-3128(08)00260-6 [pii] 10.1016/j.chom.2008.08.004.
8. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC (1995) The envelope
glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375:
291–298. doi:10.1038/375291a0.
9. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in
the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986–
6991. doi:10.1073/pnas.0832193100 0832193100 [pii].
10. Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, et al. (2012)
Mechanism of dengue virus broad cross-neutralization by a monoclonal
antibody. Structure 20: 303–314. doi:S0969-2126(12)00005-6 [pii] 10.1016/
j.str.2012.01.001.
11. Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, et al.
(2011) Structural insights into the neutralization mechanism of a higher primate
antibody against dengue virus. EMBO J 31: 767–779. doi:emboj2011439 [pii]
10.1038/emboj.2011.439.
12. Gromowski GD, Barrett AD (2007) Characterization of an antigenic site that
contains a dominant, type-specific neutralization determinant on the envelope
protein domain III (ED3) of dengue 2 virus. Virology 366: 349–360. doi:S0042-
6822(07)00379-0 [pii] 10.1016/j.virol.2007.05.042.
13. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. (2010)
The development of therapeutic antibodies that neutralize homologous and
heterologous genotypes of dengue virus type 1. PLoS Pathog 6: e1000823.
doi:10.1371/journal.ppat.1000823.
14. Wahala WM, Donaldson EF, De Alwis R, Accavitti-Loper MA, Baric RS,
et al. (2010) Natural strain variation and antibody neutralization of dengue
serotype 3 viruses. PLoS Pathog 6: e1000821. doi:10.1371/journal.ppat.
1000821.
15. Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. (2010)
Structure and function analysis of therapeutic monoclonal antibodies against
dengue virus type 2. J Virol 84: 9227–9239. doi:JVI.01087-10 [pii] 10.1128/
JVI.01087-10.
16. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the
envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317–328.
doi:S0042-6822(98)99200-5 [pii] 10.1006/viro.1998.9200.
17. Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, et al.
(2012) Structural analysis of a dengue cross-reactive antibody complexed with
Bivalent Antibody Neutralization of Dengue Virus
PLOS Pathogens | www.plospathogens.org 9 April 2014 | Volume 10 | Issue 4 | e1004072
envelope domain III reveals the molecular basis of cross-reactivity. J Immunol
188: 4971–4979. doi:10.4049/jimmunol.1200227.
18. Thompson BS, Moesker B, Smit JM, Wilschut J, Diamond MS, et al. (2009) A
therapeutic antibody against west nile virus neutralizes infection by blocking
fusion within endosomes. PLoS Pathog 5: e1000453. doi:10.1371/journal.-
ppat.1000453.
19. Wu KP, Wu CW, Tsao YP, Kuo TW, Lou YC, et al. (2003) Structural basis of a
flavivirus recognized by its neutralizing antibody: solution structure of the
domain III of the Japanese encephalitis virus envelope protein. J Biol Chem 278:
46007–46013. doi:10.1074/jbc.M307776200 M307776200 [pii].
20. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, et al. (2005)
Structural basis of West Nile virus neutralization by a therapeutic antibody.
Nature 437: 764–769. doi:nature03956 [pii] 10.1038/nature03956.
21. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al.
(2008) Binding of a neutralizing antibody to dengue virus alters the arrangement
of surface glycoproteins. Nat Struct Mol Biol 15: 312–317. doi:nsmb.1382 [pii]
10.1038/nsmb.1382.
22. Shrestha B, Austin SK, Dowd KA, Prasad AN, Youn S, et al. (2012) Complex
phenotypes in mosquitoes and mice associated with neutralization escape of a
Dengue virus type 1 monoclonal antibody. Virology 427: 127–134. doi:S0042-
6822(12)00105-5 [pii] 10.1016/j.virol.2012.02.010.
23. Lawrence MC, Colman PM (1993) Shape complementarity at protein/protein
interfaces. J Mol Biol 234: 946–950. doi:S0022-2836(83)71648-7 [pii] 10.1006/
jmbi.1993.1648.
24. Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from
crystalline state. J Mol Biol 372: 774–797. doi:S0022-2836(07)00642-0 [pii]
10.1016/j.jmb.2007.05.022.
25. Davies DR, Padlan EA, Sheriff S (1990) Antibody-antigen complexes. Annu Rev
Biochem 59: 439–473. doi:10.1146/annurev.bi.59.070190.002255.
26. Sundberg EJ, Mariuzza RA (2002) Molecular recognition in antibody-antigen
complexes. Adv Protein Chem 61: 119–160.
27. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, et al. (2008) Maturation of West Nile
Virus Modulates Sensitivity to Antibody-Mediated Neutralization. PLoS Pathog
4: e1000060. doi:10.1371/journal.ppat.1000060.
28. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC (2011) A dynamic
landscape for antibody binding modulates antibody-mediated neutralization of
West Nile virus. PLoS Pathog 7: e1002111. doi:10.1371/journal.ppat.1002111.
29. Beigel JH, Nordstrom JL, Pillemer SR, Roncal C, Goldwater DR, et al. (2010)
Safety and Pharmacokinetics of Single Intravenous Dose of MGAWN1, a Novel
Monoclonal Antibody to West Nile Virus. Antimicrob Agents Chemother 54:
2431–2436. doi:10.1128/AAC.01178-09.
30. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. (2005)
Development of a humanized monoclonal antibody with therapeutic potential
against West Nile virus. Nat Med 11: 522–530. doi:nm1240 [pii] 10.1038/
nm1240.
31. Rodrigo WWSI, Block OKT, Lane C, Sukupolvi-Petty S, Goncalvez AP, et al.
(2009) Dengue virus neutralization is modulated by IgG antibody subclass and
Fcgamma receptor subtype. Virology 394: 175–182. doi:10.1016/
j.virol.2009.09.024.
32. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC (2008)
Temperature-dependent production of pseudoinfectious dengue reporter virus
particles by complementation. Virology 381: 67–74. doi:S0042-6822(08)00525-4
[pii] 10.1016/j.virol.2008.08.021.
33. Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, et al. (2012)
Structural Basis of Differential Neutralization of DENV-1 Genotypes by an
Antibody that Recognizes a Cryptic Epitope. PLoS Pathog 8: e1002930.
doi:10.1371/journal.ppat.1002930.
34. Stiasny K, Kiermayr S, Holzmann H, Heinz FX (2006) Cryptic properties of a
cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80: 9557–
9568. doi:10.1128/JVI.00080-06.
35. Smith TJ, Olson NH, Cheng RH, Chase ES, Baker TS (1993) Structure of a
human rhinovirus-bivalently bound antibody complex: implications for viral
neutralization and antibody flexibility. Proc Natl Acad Sci USA 90: 7015–7018.
doi:10.1073/pnas.90.15.7015.
36. Hewat EA, Blaas D (1996) Structure of a neutralizing antibody bound bivalently
to human rhinovirus 2. EMBO J 15: 1515–1523.
37. Thouvenin E, Laurent S, Madelaine M-F, Rasschaert D, Vautherot J-F, et al.
(1997) Bivalent binding of a neutralising antibody to a calicivirus involves the
torsional flexibility of the antibody hinge. Journal of Molecular Biology 270:
238–246. doi:10.1006/jmbi.1997.1095.
38. Zhang W, Chipman PR, Corver J, Johnson PR, Zhang Y, et al. (2003)
Visualization of membrane protein domains by cryo-electron microscopy of
dengue virus. Nat Struct Mol Biol 10: 907–912. doi:10.1038/nsb990.
39. Kaufmann B, Nybakken GE, Chipman PR, Zhang W, Diamond MS, et al.
(2006) West Nile virus in complex with the Fab fragment of a neutralizing
monoclonal antibody. Proc Natl Acad Sci U S A 103: 12400–12404.
doi:0603488103 [pii] 10.1073/pnas.0603488103.
40. Sosnick TR, Benjamin DC, Novotny J, Seeger PA, Trewhella J (1992) Distances
between the antigen-binding sites of three murine antibody subclasses measured
using neutron and X-ray scattering. Biochemistry 31: 1779–1786. doi:10.1021/
bi00121a028.
41. Fibriansah G, Ng T-S, Kostyuchenko VA, Lee J, Lee S, et al. (2013) Structural
changes in dengue virus when exposed to a temperature of 37uC. J Virol 87:
7585–7592. doi:10.1128/JVI.00757-13.
42. Zhang X, Sheng J, Plevka P, Kuhn RJ, Diamond MS, et al. (2013) Dengue
structure differs at the temperatures of its human and mosquito hosts. Proc Natl
Acad Sci USA 110: 6795–6799. doi:10.1073/pnas.1304300110.
43. Cherrier MV, Kaufmann B, Nybakken GE, Lok SM, Warren JT, et al. (2009)
Structural basis for the preferential recognition of immature flaviviruses by a
fusion-loop antibody. EMBO J 28: 3269–3276. doi:emboj2009245 [pii]
10.1038/emboj.2009.245.
44. Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, et al. (2010)
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab
fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A
107: 18950–18955. doi:1011036107 [pii] 10.1073/pnas.1011036107.
45. De Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, et al. (2012)
Identification of human neutralizing antibodies that bind to complex epitopes on
dengue virions. Proc Natl Acad Sci USA 109: 7439–7444. doi:10.1073/
pnas.1200566109.
46. Teoh EP, Kukkaro P, Teo EW, Lim APC, Tan TT, et al. (2012) The structural
basis for serotype-specific neutralization of dengue virus by a human antibody.
Sci Transl Med 4: 139ra83. doi:10.1126/scitranslmed.3003888.
47. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002)
Structure of dengue virus: implications for flavivirus organization, maturation,
and fusion. Cell 108: 717–725. doi:S0092867402006608 [pii].
48. Modis Y, Ogata S, Clements D, Harrison SC (2004) Structure of the dengue
virus envelope protein after membrane fusion. Nature 427: 313–319.
doi:10.1038/nature02165 nature02165 [pii].
49. Brien JD, Austin SK, Sukupolvi-Petty S, O’Brien KM, Johnson S, et al. (2010)
Genotype-specific neutralization and protection by antibodies against dengue
virus type 3. J Virol 84: 10630–10643. doi:JVI.01190-10 [pii] 10.1128/
JVI.01190-10.
50. Thomas AA, Vrijsen R, Boeye A (1986) Relationship between poliovirus
neutralization and aggregation. J Virol 59: 479–485.
51. Kaufmann B, Chipman PR, Holdaway HA, Johnson S, Fremont DH, et al.
(2009) Capturing a flavivirus pre-fusion intermediate. PLoS Pathog 5: e1000672.
doi:10.1371/journal.ppat.1000672.
52. Smith TJ, Olson NH, Cheng RH, Liu H, Chase ES, et al. (1993) Structure of
human rhinovirus complexed with Fab fragments from a neutralizing antibody.
J Virol 67: 1148–1158.
53. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. (2010)
Polyreactivity increases the apparent affinity of anti-HIV antibodies by
heteroligation. Nature 467: 591–595. doi:nature09385 [pii] 10.1038/na-
ture09385.
54. Zhu P, Liu J, Bess J, Chertova E, Lifson JD, et al. (2006) Distribution and three-
dimensional structure of AIDS virus envelope spikes. Nature 441: 847–852.
doi:nature04817 [pii] 10.1038/nature04817.
55. Schofield DJ, Stephenson JR, Dimmock NJ (1997) Variations in the neutralizing
and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs
and their antibody fragments. J Gen Virol 78 (Pt 10): 2431–2439.
56. Klasse PJ, Sattentau QJ (2002) Occupancy and mechanism in antibody-
mediated neutralization of animal viruses. J Gen Virol 83: 2091–2108.
57. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in
oscillation mode. In: C.W. Carter J& RMS, editors. Methods in Enzymology.
New York: Academic Press. pp. 307–326.
58. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al.
(2007) Phaser crystallographic software. J Appl Crystallogr 40: 658–674.
doi:10.1107/S0021889807021206.
59. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr 60: 2126–2132. doi:S0907444904019158
[pii] 10.1107/S0907444904019158.
60. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystal-
logr 53: 240–255. doi:10.1107/S0907444996012255 S0907444996012255 [pii].
61. Adams PD, Afonine PV, Bunko´czi G, Chen VB, Davis IW, et al. (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure
solution. Acta Crystallographica Section D Biological Crystallography 66: 213–
221. doi:10.1107/S0907444909052925.
62. Potterton L, McNicholas S, Krissinel E, Gruber J, Cowtan K, et al. (2004)
Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol
Crystallogr 60: 2288–2294. doi:10.1107/S0907444904023716.
63. DeLano WL (2008) The PyMOL Molecular Graphics System, version 1.
Schro¨dinger, LLC (Oregon).
64. Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, et al. (2009)
Human monoclonal antibodies against West Nile virus induced by natural
infection neutralize at a postattachment step. J Virol 83: 6494–6507.
doi:JVI.00286-09 [pii] 10.1128/JVI.00286-09.
65. Mattia K, Puffer BA, Williams KL, Gonzalez R, Murray M, et al. (2011)
Dengue reporter virus particles for measuring neutralizing antibodies against
each of the four dengue serotypes. PLoS ONE 6: e27252. doi:10.1371/
journal.pone.0027252.
Bivalent Antibody Neutralization of Dengue Virus
PLOS Pathogens | www.plospathogens.org 10 April 2014 | Volume 10 | Issue 4 | e1004072
